Skip to the content
  • Suomeksi
  • About Us
    • > Our role
    • > BoD and management
    • > Sustainability
  • Pharma Sector
    • > Feasibilities and inquiries
    • > Research archive
    • > References for post-licensure studies
  • Newsfeed
  • Contacts
  • Suomeksi

Sustainability: focus on people’s wellbeing and safety

FVR is a young company that started operations in 2022. An important part of the development of our new Finnish state owned special-assignment company is the setting of the sustainability roadmap, focus areas and KPIs. This work was launched with a materiality analysis, where the company’s key stakeholders were consulted and the most relevant aspects impacting the sustainability of our operations were identified. Based on the materiality analysis, we created FVR’s first sustainability agenda and indicators. These will evolve over time, together with our operations.

Overview of 2024

FVR’s first full year of operations met and even exceeded expectations in many areas.

read the overview

Materiality analysis and key impacts

FVR offers research services. We have no manufacturing or production activities or our own products that generate life-cycle emissions. Due to our focus on vaccine research, our greatest impact is created through the promotion of people’s wellbeing, health and safety. The main impact areas here are:

  • Public health and disease prevention. We play an important role as a content producer, distributor and participant in discussions of science-based information, as well as a promoter of national and global vaccine acceptance.
  • Ethical operating methods and secure processing of research and personal data are central to our operations. Openness and transparency in the company’s administration and decision-making are also important.
  • The wellbeing, motivation and skills of our own personnel, as well as their development, are essential in ensuring the safety and health of the volunteers participating in the studies.

UN Global Compact

FVR has joined the United Nations’ Global Compact initiative — a voluntary leadership platform for the development, implementation and disclosure of responsible business practices. This means we are committed to align our operations and strategies with ten universally accepted principles in the areas of human rights, labour, environment and anti-corruption, and to take action in support of UN goals and issues embodied in the Sustainable Development Goals (SDGs).
Read more about the Global Compact >>
Read about the 10 principles >>

Code of Conduct

fvr code of conduct

FVR’s ethical guidelines for personnel and partners are summarized in the company’s Code of Conduct.

Whistleblowing

whistleblowing

Through the whistleblowing channel, stakeholders can confidentially report cases where any violation of the law, official regulations, FVR’s values ​​or Code of Conduct is suspected.

Focus areas and KPIs

(Results for 2023 can be found in the overview report >> )

PEOPLE

Own employees
Wellbeing at work:
”I would recommend FVR as an employer” >70%

Private persons
Satisfaction of research volunteers:
Happy Index >80/100 (digital feedback from research clinics)

Pro-vaccination attitudes
Willingness to participate in vaccine studies of common adult vaccine-preventable diseases: More registered volunteers than the country-specific target for studies (N)

GOOD GOVERNANCE AND FINANCIAL SUSTAINABILITY

Data protection and data security
ISO 27001 certification qualified by the end of 2024

Ethical business conduct
Code of Conduct:
100% of staff trained each year

Financial sustainability
Profitable growth

Risk management and quality
ISO 9001 certification-readiness by the end of 2024 (certification 2025)

ENVIRONMENT

Energy consumption
Baseline analysis done and goals set by the end of 2024

Travel
Baseline analysis done and goals set by the end of 2024

Procurement
Sustainability criteria defined and implemented for procurement by the end of 2024

Paperless office
Goals set and roadmap defined by the end of 2023

  • About Us
    • Our role
    • BoD and management
    • Sustainability
  • Pharma Sector
    • Feasibilities and inquiries
    • Research archive
    • References for post-licensure studies
  • Newsfeed
  • Contacts

FVR - Finnish Vaccine Research
Peltokatu 26, 33100 Tampere, Finland
info@fvr.fi Business ID FI32566594

  • About cookies

© Copyrights 2022 FVR – Finnish Vaccine Research